Table 2

Patient clinical characteristics of B-cell lymphoma (NCT03101709)

IDAge/genderLines of prior therapyPrevious treatmentMarrow blasts before therapyLymphocyte depletionWBC (109/L)LYM (109/L)Peripheral blood collection (mL)PBMC collection (×107)CD3+ T cell collection (×107)CD3+ T cells for culture (×107)Transfection efficiency (%)CAR dose (×106/kg)CRS gradeResponse (2 months)
152/M6CYFC8.433.611006.263.162.4373.01CR
239/F3CNFC2.540.761005.302.702.4312.00PR
335M3CYFC6.151.741006.884.692.4421.52CR
460/F3CNFC3.250.851004.902.602.4451.50PD
551/F3C, R, TNFC5.450.491003.952.132.0301.50CR
662/M4CNFC2.660.831004.962.662.4201.00PD
758/F4CNFC2.520.751007.334.902.4602.02PR
849/M3CNFC11.600.911008.003.462.4451.51CR
938/M3CNFC4.351.471007.405.302.4391.51PR

All patients were followed up until February 5, 2018; M, male; F, female; C, chemotherapy; R, radiation therapy; T, hemopoietic stem-cell transplant; CRS, cytokine release syndrome; PBMC, peripheral blood mononuclear cell; WBC, white blood cell, normal range (3.5–9.5) × 109/L; LYM, lymphocyte count, normal range (1.1–3.2) × 109/L; FC, fludarabine, cyclophosphamide; N, no; Y, yes; CR, complete remission; PR, partial remission; PD, progressive disease.